Drug · DIN 02435470
FORXIGA
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since January 16, 2015; first marketed January 16, 2015.
- Drug Identification Number (DIN)
- 02435470
- Company (DIN owner)
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Dapagliflozin A10BK01
- Class
- Human
- Record last updated
- June 16, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| DAPAGLIFLOZIN (DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE) | 10 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- August 10, 2016: NOC 18352Supplement to a New Drug Submission (SNDS) · Update to the product monograph in response to an advisement letter issued april 15, 2016
- December 12, 2014: NOC 16433New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “forxiga”. A notice may cover another product or only some lots: read it to see what it covers.
- SGLT2 Inhibitors [INVOKANA (canagliflozin), FORXIGA (dapagliflozin), XIGDUO (dapagliflozin/metformin), JARDIANCE (empagliflozin)] - Risk of Diabetic KetoacidosisMay 16, 2016 · Drugs · Product safety
- Forxiga, Invokana: Health Canada begins safety review of diabetes drugs known as SGLT2 inhibitors and risk of ketoacidosisJune 22, 2015 · Drugs · Product safety
Other DINs named FORXIGA
- DIN 02435462 · Marketed